Drug Database
Back to search

Netherlands· NL-06123b0f3387

Ultomiris 300 mg/3 ml concentraat voor oplossing voor infusie

A ravulizumab product containing ravulizumab, registered in Netherlands by Alexion Europe S.A.S.. The same ATC class is registered in 12 of our 19 countries.

ATC L04AJ02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedUltomiris 300 mg/3 ml concentraat voo…ATCL04AJ02REGISTER NO.NL-06123b0f3387PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ravulizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ravulizumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AJ02 (ravulizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search ravulizumab products by name

Ravulizumab · ATC L04AJ02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
RAVULIZUMAB
Manufacturer
Alexion Europe S.A.S.
Country
Netherlands (NL)
ATC code
L04AJ02
ATC class
Ravulizumab
Defined daily dose
70 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/19/1371

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for ravulizumab.

Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ravulizumab against other medicinesHow interaction checks work

Ravulizumab · interactions on record

2 records

  • 2 minor

Most severe, free to view

    Mechanism and what to do, in the interaction check
    Interaction register. Grades as the source publishes them.

    Same medicine, other countries

    Ravulizumab in 15 other countries

    What each register calls a product with the same active substance — salts and hydrates count as the same.

    All ravulizumab products

    Authorised across Europe · EMA

    The same active substance is authorised in 3 EEA countries. Names it is sold under:

    • Iceland · Ultomiris
    • Liechtenstein · Ultomiris
    • Norway · Ultomiris

    Source: European Medicines Agency, Article 57 product data.

    Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

    For developers

    The same record over the API, and the raw payload
    GET /v1/drugs/e2558b02-af39-481d-a1e5-15d5337494d5
GET /v1/drugs/e2558b02-af39-481d-a1e5-15d5337494d5?format=fhir

    Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

    {
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ravulizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp123410",
  "excipients": [
    "ARGININE, (L-)",
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "POLYSORBAAT 80 (E 433)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "RAVULIZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2019/07/02",
  "procedure_number": "EMEA/H/C/004954",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/19/1371",
  "additional_monitoring": "N"
}
    API referenceMCP serverPlans

    See everything about ravulizumab.

    This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

    Try it freeOpen in the console